Lacnotuzumab Biosimilar - Research Grade

Human

CSF1

>1mg/ml

IgG1 - kappa

CHO Cells

Anti-Mouse CSF1 (5A1) In Vivo Antibody - Low Endotoxin (ICH1280)

https://www.imgt.org/mAb-DB/

ICH3002

P09603

1435

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of lacnotuzumab (originator designation MCS110), a fully human antibody directed against the cytokine CSF1 (macrophage colony-stimulating factor, M-CSF). Built as a human IgG1/kappa molecule around the CSF1 target, it is intended strictly for research use (RUO) and is not the clinical drug, nor is it for human or veterinary use. Because it binds the soluble ligand CSF1 rather than its receptor, it is a useful reagent for studying the CSF1/CSF1R signaling axis, macrophage and monocyte biology, and tumor-associated macrophage (TAM) recruitment in controlled experiments. Typical applications include ligand-neutralization assays, positive and isotype-matched controls, epitope and binding characterization, and preclinical in-vitro or ex-vivo model systems. The material is offered at research grade with low endotoxin (typically <1 EU/mg, with an ultra-low <0.5 EU/mg option) and is available in bulk milligram-to-gram quantities to support screening, assay development, and reproducibility studies where consistent, well-characterized reagent supply matters. CSF1 (colony-stimulating factor 1, also called M-CSF) is a secreted, disulfide-linked homodimeric cytokine that is the principal growth factor governing the survival, proliferation, differentiation, and function of mononuclear phagocytes, including monocytes, macrophages, and osteoclasts. It signals through the receptor tyrosine kinase CSF1R (CD115), and shares that receptor with the unrelated ligand IL-34. CSF1 undergoes complex proteolytic processing and glycosylation, yielding secreted and cell-surface forms. Beyond steady-state myeloid homeostasis, it drives osteoclast-mediated bone resorption, contributes to innate immunity and inflammatory chemokine release, and supports fertility and placental function. Aberrant CSF1 expression is implicated in tumor progression through recruitment and polarization of immunosuppressive tumor-associated macrophages, and in inflammatory conditions such as rheumatoid arthritis and atherosclerosis, making the CSF1/CSF1R axis an intensively studied target.

M-CSF, Lanimostim, Proteoglycan macrophage colony-stimulating factor, PG-M-CSF, Macrophage colony-stimulating factor 1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Lacnotuzumab (anti-CSF1) Biosimilar

Q: Is the Lacnotuzumab biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Lacnotuzumab biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Lacnotuzumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Lacnotuzumab that binds CSF1; for research use only.